Evidence map›Paper›PMID 36689584›Full record

Trial reportStroke2023

Symptomatic Intracranial Hemorrhage After Endovascular Stroke Treatment: External Validation of Prediction Models.

Nadinda A M van der Ende, Femke C C Kremers, Wouter van der Steen, Esmee Venema, Manon Kappelhof, Charles B L M Majoie, Alida A Postma, Jelis Boiten, Ido R van den Wijngaard, Aad van der Lugt and 3 more

Open access · hybridAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Stroke, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Nadinda A M van der EndeDepartments of Neurology (N.A.M.v.d.E, F.C.C.K., W.v.d.S, E.V., D.W.J.D., B.R.), Erasmus MC University Medical Center, the Netherlands.ORCID 0000-0003-4681-8388
Femke C C KremersDepartments of Neurology (N.A.M.v.d.E, F.C.C.K., W.v.d.S, E.V., D.W.J.D., B.R.), Erasmus MC University Medical Center, the Netherlands.ORCID 0000-0002-7189-1600
Wouter van der SteenDepartments of Neurology (N.A.M.v.d.E, F.C.C.K., W.v.d.S, E.V., D.W.J.D., B.R.), Erasmus MC University Medical Center, the Netherlands.ORCID 0000-0001-9428-1920
Esmee VenemaDepartments of Neurology (N.A.M.v.d.E, F.C.C.K., W.v.d.S, E.V., D.W.J.D., B.R.), Erasmus MC University Medical Center, the Netherlands.ORCID 0000-0003-1631-6635
Manon KappelhofDepartment of Radiology and Nuclear Medicine (M.K.), Amsterdam UMC, University of Amsterdam, the Netherlands.ORCID 0000-0001-5250-8955
Charles B L M MajoieORCID 0000-0002-7600-9568
Alida A PostmaDepartment of Radiology and Nuclear Medicine, School for Mental Health and Sciences, Maastricht University Medical Center, the Netherlands (A.A.P.).ORCID 0000-0002-1116-054X
Jelis BoitenDepartments of Neurology (J.B., I.R.v.d.W.), Haaglanden Medical Center, the Netherlands.
Ido R van den WijngaardDepartments of Neurology (J.B., I.R.v.d.W.), Haaglanden Medical Center, the Netherlands.ORCID 0000-0002-3734-6086
Diederik W J DippelDepartments of Neurology (N.A.M.v.d.E, F.C.C.K., W.v.d.S, E.V., D.W.J.D., B.R.), Erasmus MC University Medical Center, the Netherlands.ORCID 0000-0002-9234-3515
Bob RoozenbeekDepartments of Neurology (N.A.M.v.d.E, F.C.C.K., W.v.d.S, E.V., D.W.J.D., B.R.), Erasmus MC University Medical Center, the Netherlands.ORCID 0000-0002-8320-8303
MR CLEAN Registry Investigators
Erasmus MC · NLMedisch Centrum Haaglanden · NLAmsterdam Neuroscience · NLMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSymptomatic intracranial hemorrhage (sICH) is a severe complication of reperfusion therapy for ischemic stroke. Multiple models have been developed to predict sICH or intracranial hemorrhage (ICH) after reperfusion therapy. We provide an overview of published models and validate their ability to predict sICH in patients treated with endovascular treatment in daily clinical practice.

methodsWe conducted a systematic search to identify models either developed or validated to predict sICH or ICH after reperfusion therapy (intravenous thrombolysis and/or endovascular treatment) for ischemic stroke. Models were externally validated in the MR CLEAN Registry (n=3180; Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). The primary outcome was sICH according to the Heidelberg Bleeding Classification. Model performance was evaluated with discrimination (c-statistic, ideally 1; a c-statistic below 0.7 is considered poor in discrimination) and calibration (slope, ideally 1, and intercept, ideally 0).

resultsWe included 39 studies describing 40 models. The most frequently used predictors were baseline National Institutes of Health Stroke Scale (NIHSS; n=35), age (n=22), and glucose level (n=22). In the MR CLEAN Registry, sICH occurred in 188/3180 (5.9%) patients. Discrimination ranged from 0.51 (SPAN-100 [Stroke Prognostication Using Age and National Institutes of Health Stroke Scale]) to 0.61 (SITS-SICH [Safe Implementation of Treatments in Stroke Symptomatic Intracerebral Hemorrhage] and STARTING-SICH [STARTING Symptomatic Intracerebral Hemorrhage]). Best calibrated models were IST-3 (intercept, -0.15 [95% CI, -0.01 to -0.31]; slope, 0.80 [95% CI, 0.50-1.09]), SITS-SICH (intercept, 0.15 [95% CI, -0.01 to 0.30]; slope, 0.62 [95% CI, 0.38-0.87]), and STARTING-SICH (intercept, -0.03 [95% CI, -0.19 to 0.12]; slope, 0.56 [95% CI, 0.35-0.76]).

conclusionsThe investigated models to predict sICH or ICH discriminate poorly between patients with a low and high risk of sICH after endovascular treatment in daily clinical practice and are, therefore, not clinically useful for this patient population.

Indexed as

Brain IschemiaEndovascular ProceduresIschemic StrokeStrokeCerebral HemorrhageFibrinolytic AgentsHumansIntracranial HemorrhagesRisk FactorsTissue Plasminogen ActivatorTreatment OutcomeFibrinolytic AgentsTissue Plasminogen Activatorendovascular treatmentischemic strokesymptomatic intracranial hemorrhage

Identifiers

PMID36689584
PMCPMC9855739
OpenAlexW4317871251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.